Wire Stories
CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (1228.HK),...